TL;DR
This study reveals that Autosomal-Dominant Hypocalcemia Type 1 (ADH1), a rare genetic disorder, is significantly underdiagnosed. By developing a novel scoring system and analyzing large population datasets, researchers identified new variants contributing to ADH1, suggesting a broader spectrum of the disease and a greater symptom burden than previously understood.
What Problem Does This Paper Address?
Rare genetic disorders, like Autosomal-Dominant Hypocalcemia Type 1 (ADH1), are often challenging to diagnose and characterize. ADH1 is caused by gain-of-function (GoF) variants in the calcium-sensing receptor (CaSR) gene, leading to low calcium levels (hypocalcemia). Historically, studies have relied on small, clinically ascertained cohorts, potentially missing a significant portion of affected individuals and underestimating the full spectrum of symptoms and variant effects. The problem is that existing diagnostic approaches and understanding of ADH1 are limited, leading to underdiagnosis and an incomplete picture of the disease's prevalence and impact in the general population. This paper aims to address this by leveraging large-scale genomic data to identify new ADH1-associated variants and better define the disease's burden.
Methods
The researchers developed a novel "ADH1 score" to identify potential ADH1-associated variants. This score is a weighted sum of several factors:
- Variant characteristics: This includes the variant's location within the protein (especially in known "hotspots" for GoF variants) and its predicted pathogenicity using in silico tools (Varsome).
- ADH1 phenotypes: This incorporates the variant's association with serum calcium and phosphate levels, as well as its presence in individuals with ADH1-related diagnosis codes or medications.
This score was applied to rare missense/stop-gain variants in the CASR gene within large population-based cohorts. To validate their findings, they also performed:
- In vitro functional assays: This involved expressing specific CASR variants in cell lines to test their response to extracellular calcium.
- Genetic sequencing: They sequenced individuals with non-surgical hypoparathyroidism to further validate identified variants.
- Phenome-wide association studies (pheWAS): This was used to explore a broader range of potential clinical manifestations associated with CASR variants.
Datasets
The study utilized data from three large population-based biobanks:
- UK Biobank (UKB): Approximately 433,793 participants.
- All of Us (AOU): Approximately 229,987 participants.
- Mass General Brigham Biobank (MGB): Approximately 39,081 participants.
Additionally, they used genetic sequencing data from 169 individuals with non-surgical hypoparathyroidism for validation.
Key Insights and Ideas
- ADH1 is significantly underdiagnosed: A striking finding is that a large proportion of individuals with known ADH1-associated variants in large biobanks lacked an ADH1-related diagnosis code, suggesting many cases go unrecognized.
- A novel scoring system can uncover new variants: The developed "ADH1 score" effectively distinguished between pathogenic and benign variants, enabling the identification of nine previously unrecognized low-frequency variants associated with ADH1.
- An "allelic series" for CaSR function: The newly identified variants, along with previously known ones, form a spectrum (allelic series) of CASR variants that influence serum calcium levels. This series bridges the gap between common variants affecting calcium and rare, highly penetrant ADH1 variants.
- Broader symptom burden: The study suggests that ADH1 may present with a wider range of symptoms than previously appreciated, including potential links to coagulation defects and tooth disorders.
- Population-level insights are crucial for rare diseases: This work highlights the power of using large population datasets to understand the true prevalence, penetrance, and expressivity of rare genetic disorders, which is often missed in smaller, clinically ascertained cohorts.
Key Results
- Underdiagnosis: In the UKB, only 17% of individuals with known ADH1 variants had an ADH1-relevant diagnosis code, while in AOU, this was 44%. This contrasts with the observed hypocalcemia in 60% (UKB) and 78% (AOU) of these individuals.
- New Variants Identified: The ADH1 scoring algorithm identified nine novel low-frequency CASR variants associated with ADH1. These variants, when combined, contribute a symptom burden equivalent to all previously reported ADH1-associated variants.
- Increased Prevalence: The newly identified variants are found at a significantly higher frequency (8.3E-5) compared to previously established ADH1 variants (6.9E-6).
- Functional Validation: In vitro assays confirmed that some of the newly identified variants exhibit altered sensitivity to extracellular calcium, supporting their role in ADH1.
- Symptom Burden: The study estimates a symptomatic prevalence of 0.3-2.0 per 100,000 for previously reported ADH1 variants and an additional 3.7 per 100,000 from the nine newly identified variants in the UKB.
Limitations and Future Work
- Sample Size for Novel Variants: While the study analyzed large cohorts, the number of individuals with known ADH1 variants was still limited (n < 30), potentially limiting the power for hypothesis-free modeling.
- In Vitro Assay Limitations: The in vitro calcium mobilization assay captures only one dimension of CaSR activity, and pEC50 values did not directly correlate with variant penetrance, suggesting other factors influence disease manifestation.
- Future Work: The authors suggest that future research should explore environmental factors and polygenic scores (incorporating genes involved in calcium homeostasis) to better understand the modifiers of CASR variant penetrance. They also propose that the developed framework can be adapted for identifying and characterizing variants in other rare genetic diseases, emphasizing the need for ever-growing, diverse cohorts to deepen understanding of disease variability.
Summary updated